BCR and acute lymphoblastic leukemia: Several studies have identified the combination of TKI with blinatumomab as treatment option for BCR::ABL1+ B-ALL patients (Assi et al. 2017; Chiaretti et al. 2019; King et al. 2019; Foa et al. 2020); however, uncertainty remains regarding drug sequence, combination and dosing.